Ventus Therapeutics is a technology company.
Ventus Therapeutics has raised $300.0M across 3 funding rounds.
Ventus Therapeutics has raised $300.0M in total across 3 funding rounds.
Ventus Therapeutics has raised $300.0M in total across 3 funding rounds.
Ventus Therapeutics's investors include GV, OrbiMed, Versant Ventures.
Ventus Therapeutics is a clinical-stage biopharmaceutical company specializing in structure-based drug discovery for immunology, inflammation, and neurology disorders.[1][2][3] It develops small-molecule therapeutics using its proprietary ReSOLVE platform, which integrates AI/ML, protein science, structural biology, and biophysics to target previously undruggable innate immune pathways.[1][2][3][5] The company serves patients with autoimmune diseases (e.g., lupus), neurological conditions (e.g., Parkinson's, Alzheimer's), and inflammatory disorders by addressing unmet needs where existing therapies fall short.[2][3] Key programs include VENT-02 (brain-penetrant NLRP3 inhibitor in Phase 2 for Parkinson's) and VENT-03 (first-in-class cGAS inhibitor entering Phase 2 for lupus in 2025), alongside partnerships like VENT-01 with Novo Nordisk.[2][3][5] Founded in 2020, Ventus has shown rapid growth, advancing from target screening to multiple Phase 2 trials and securing $60M in Series A funding.[4][5]
Ventus Therapeutics was founded in 2020 by Versant Ventures in Waltham, Massachusetts (with some early ties noted to Canada), launching with a $60M Series A led by Versant and GV (Google Ventures).[1][4][6] The idea emerged from breakthroughs in structural immunology, targeting innate immune pathways undruggable by traditional methods, inspired by genetics and clinical evidence in autoimmune diseases, inflammation, and oncology.[4] Key scientific co-founders and advisors include experts like Judith Lieberman, MD, PhD, who contributed to protein engineering and innate immunity insights.[4][5] Marcelo Bigal, MD, PhD, serves as President and CEO, bringing drug discovery and commercialization experience.[2][4] Early traction was swift: the first target screen in 2020 yielded three development candidates by 2022 (VENT-01, -02, -03), with Phase 1 initiation for VENT-02 in 2023 and a high-value Novo Nordisk partnership.[2][5]
Ventus stands out in biopharma through its focus on challenging innate immune targets. Key strengths include:
Competitors like Azome Therapeutics trail in similar structure-based approaches, but Ventus's platform yields faster, more robust pipelines.[1]
Ventus rides the wave of AI-driven drug discovery and innate immunity targeting, capitalizing on validated biology from genetics (e.g., IL-1B, interferons) and rising demand for oral small molecules in neurology and autoimmunity.[3][4] Timing aligns with post-2020 advances in structural biology tools, enabling "undruggable" targets like cGAS and NLRP3 amid failures by others.[2] Market forces favor it: aging populations drive neurology needs (Parkinson's, Alzheimer's), while autoimmune diseases like lupus lack sufficient therapies; oncology synergies via immune modulation add upside.[1][4] Ventus influences the ecosystem by validating ReSOLVE for partnerships (e.g., Novo Nordisk) and accelerating Phase 2 readouts, potentially reshaping standards for computational biopharma platforms.[2][5]
Ventus is poised for inflection with Phase 2 data from VENT-02 (Parkinson's) and VENT-03 (lupus) in the next 12-18 months, potentially proving ReSOLVE's edge in high-unmet-need areas.[3][5] Trends like AI-biophysics integration and brain-penetrant therapies will amplify growth, with expansion into oncology and more partnerships likely. Its influence may evolve from nimble innovator to pipeline leader, delivering first-in-class options that redefine innate immunity treatments—echoing its launch as a Versant-backed disruptor now translating structure into patient impact.[2][4][5]
Ventus Therapeutics has raised $300.0M across 3 funding rounds. Most recently, it raised $140.0M Series C in February 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2022 | $140.0M Series C | GV, OrbiMed, Versant Ventures | |
| Apr 1, 2021 | $100.0M Series B | GV, OrbiMed, Versant Ventures | |
| May 1, 2020 | $60.0M Series A | GV, OrbiMed, Versant Ventures |